Our Pricing

Orlistat vs Wegovy: Which Weight Loss Treatment Is Right for You?

When comparing orlistat vs wegovy, UK patients often face a critical decision between two fundamentally different weight loss approaches. Orlistat works by blocking fat absorption in the digestive system, while Wegovy (semaglutide) acts as a GLP-1 receptor agonist that regulates appetite and blood sugar. Understanding the clinical evidence, side effect profiles, and practical considerations between these two licensed treatments helps you make an informed choice with your prescriber.

How Orlistat vs Wegovy Mechanisms Differ

The fundamental difference in the orlistat vs wegovy comparison lies in their mechanisms of action. Orlistat 120mg works locally in your gastrointestinal tract by inhibiting pancreatic and gastric lipases—enzymes responsible for breaking down dietary fats into absorbable molecules [1]. By blocking approximately 25-30% of dietary fat absorption, orlistat prevents those calories from entering your bloodstream, instead passing them through your digestive system unabsorbed.

Wegovy operates through an entirely different pathway as a GLP-1 (glucagon-like peptide-1) receptor agonist. Administered as a once-weekly subcutaneous injection, semaglutide mimics the natural GLP-1 hormone that regulates appetite centres in your brain, slows gastric emptying, and improves insulin sensitivity [2]. This systemic approach means Wegovy influences multiple metabolic pathways simultaneously, whereas orlistat's action remains confined to fat digestion in the gut.

From a clinical pharmacology perspective, this mechanistic distinction shapes every aspect of how these treatments perform. Orlistat requires consistent adherence with each fat-containing meal and works only when dietary fat is present. Wegovy maintains steady therapeutic levels throughout the week, providing continuous appetite regulation regardless of meal timing. Neither approach is inherently superior—the optimal choice depends on your lifestyle, medical history, and weight loss goals as assessed by your UK prescriber.

Clinical Efficacy: Orlistat vs Wegovy Weight Loss Results

Clinical trial data reveals substantial differences when examining orlistat vs wegovy efficacy. The XENDOS trial demonstrated that orlistat 120mg three times daily, combined with lifestyle modification, produced an average weight loss of 5.8kg over four years compared to 3.0kg with placebo—representing approximately 5-10% total body weight reduction in most patients [1]. Real-world UK clinical experience shows similar results, with patients losing an average of 5-8% of their initial body weight over 12 months when adhering to the prescribed regimen.

Wegovy demonstrates markedly higher weight reduction in the STEP clinical trial programme. The pivotal STEP 1 trial showed participants achieved an average 14.9% body weight reduction over 68 weeks with semaglutide 2.4mg weekly, compared to 2.4% with placebo [2]. In the UK population specifically, STEP 8 data confirmed average weight loss of 15.8% with Wegovy versus 6.4% with liraglutide (another GLP-1 agonist), establishing semaglutide as the most effective pharmacological obesity treatment currently licensed [3].

When our clinical team at Cured Pharmacy reviews the orlistat vs wegovy evidence with patients, we emphasise that higher efficacy comes with different considerations. Wegovy requires weekly injections, costs more, and carries a different side effect profile. Orlistat offers a non-systemic option with established long-term safety data spanning over two decades of clinical use. The 'better' choice depends entirely on individual circumstances, including BMI, comorbidities, previous treatment responses, and personal preferences—all factors assessed during your online consultation with our UK-registered prescribers.

Comparative Weight Loss Outcomes at 12 Months

At the 12-month mark, the orlistat vs wegovy comparison shows distinct outcome patterns. Orlistat-treated patients typically achieve 5-10% body weight reduction, with maximum benefit seen when combined with a reduced-calorie, lower-fat diet (approximately 30% of calories from fat). Wegovy patients commonly reach 12-17% body weight reduction by month 12, with some individuals achieving over 20% reduction in clinical trials [2]. Both treatments require ongoing use to maintain weight loss—discontinuation typically results in weight regain regardless of which medication you've used.

Side Effects Profile: Orlistat vs Wegovy Tolerability

The side effect profiles differ dramatically in the orlistat vs wegovy comparison, reflecting their distinct mechanisms. Orlistat's most common adverse effects are gastrointestinal and directly related to its fat-blocking action: oily spotting, flatulence with discharge, faecal urgency, and oily or fatty stools [1]. These effects are most pronounced when patients consume meals containing more than 15-20g of fat, and typically diminish as patients adapt their dietary fat intake. Importantly, these are local effects confined to the digestive system with minimal systemic absorption.

Wegovy's side effect profile centres on gastrointestinal symptoms that result from its systemic GLP-1 activity: nausea (reported in 44% of trial participants), diarrhoea (30%), vomiting (24%), constipation (24%), and abdominal pain (20%) [2]. These effects are typically most pronounced during dose escalation and often improve over 4-8 weeks as your body adapts. Unlike orlistat's predictable relationship with dietary fat, Wegovy's side effects occur independently of meal composition and are related to slowed gastric emptying and central appetite regulation.

In our experience at Cured Pharmacy, patient tolerability in the orlistat vs wegovy decision often comes down to lifestyle factors. Active professionals who eat unpredictably or frequently dine out sometimes find orlistat's gastrointestinal effects challenging to manage discreetly. Conversely, patients with a history of gastroparesis, severe GERD, or previous intolerance to GLP-1 medications may find Wegovy poorly tolerated. Both treatments are generally well-tolerated when patients receive proper counselling about what to expect and how to minimise side effects through dietary adjustments and gradual dose titration where applicable.

Managing Side Effects with Each Treatment

Practical side effect management differs significantly in the orlistat vs wegovy context. For orlistat, the key strategy involves distributing your daily fat intake evenly across three main meals (ideally 15g fat per meal or less), avoiding high-fat foods, and taking the capsule during or up to one hour after each meal. For Wegovy, strategies include eating smaller portions, avoiding high-fat or spicy foods that slow digestion further, staying well-hydrated, and allowing the full 4-week intervals between dose increases to permit physiological adaptation [3]. Your UK prescriber will provide personalised guidance based on your individual response.

Cost Comparison: Orlistat vs Wegovy UK Pricing

The financial aspect of the orlistat vs wegovy decision represents one of the most significant practical differences for UK patients. At Cured Pharmacy, orlistat 120mg is available from £69.00 for a one-month supply (84 capsules), making it the most accessible prescription weight loss treatment currently available. With the code Weightlossnew, new patients receive £20 off their first order, further reducing the initial cost barrier. This pricing reflects orlistat's status as an established generic medication with multiple manufacturers, driving competitive UK market pricing.

Wegovy pricing reflects its position as a newer, patent-protected biological medication with substantially higher manufacturing complexity. At Cured Pharmacy, Wegovy is available from £69.00, representing competitive UK pricing for this GLP-1 treatment. When evaluating the orlistat vs wegovy cost difference, patients should consider the higher efficacy data associated with Wegovy—the cost per kilogram of weight lost may actually be comparable despite the higher absolute price, particularly for patients who achieve the average 15% body weight reduction seen in clinical trials [2].

Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), advises patients to consider total cost of treatment over 6-12 months when comparing orlistat vs wegovy options. Orlistat requires three capsules daily for continuous effect, while Wegovy involves one injection weekly. Neither treatment should be viewed as a short-term intervention—clinical evidence shows weight loss maintenance requires ongoing pharmacological support in most patients. During your free online consultation, our UK-registered clinical team will discuss which option aligns with both your clinical needs and financial circumstances, ensuring transparent pricing before you proceed with any prescription.

Eligibility Criteria: Orlistat vs Wegovy Prescribing Guidelines

UK prescribing criteria differ when comparing orlistat vs wegovy eligibility. Orlistat is licensed for adults with a BMI of 30 kg/m² or above, or 28 kg/m² or above in the presence of weight-related comorbidities such as type 2 diabetes, hypertension, or dyslipidaemia [1]. NICE guidance supports orlistat as a first-line pharmacological option when lifestyle interventions alone have been insufficient, making it accessible to a broad patient population. There are relatively few absolute contraindications—chronic malabsorption syndrome and cholestasis being the primary exclusions.

Wegovy prescribing in the UK follows more restrictive criteria aligned with its MHRA licence and NICE guidance. Semaglutide 2.4mg is indicated for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity [2]. However, practical prescribing often prioritises Wegovy for patients who have not achieved adequate weight loss with other interventions, including orlistat, or those with significant metabolic complications where greater weight reduction is clinically necessary. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe gastrointestinal disease.

When our clinical team evaluates orlistat vs wegovy suitability during online consultations, we assess multiple factors beyond BMI alone. Medical history screening identifies any contraindications, current medications are reviewed for potential interactions (particularly warfarin with orlistat, which can affect vitamin K absorption), and previous weight loss attempts help predict likely treatment response. Both medications require commitment to lifestyle modification—neither works effectively without dietary changes and increased physical activity. Your UK prescriber will determine which treatment aligns with your individual clinical profile and weight management goals.

Special Populations and Contraindications

Certain populations require particular consideration in the orlistat vs wegovy decision. Neither medication is licensed for use during pregnancy or breastfeeding, and both require effective contraception in women of childbearing potential. Orlistat may reduce absorption of fat-soluble vitamins (A, D, E, K) and oral contraceptives, necessitating supplementation and additional contraceptive precautions [1]. Wegovy is contraindicated in patients with diabetic retinopathy or a history of pancreatitis, and requires careful monitoring in those with renal impairment [3]. Age over 75 or under 18 generally precludes prescribing for either medication without specialist input. Your prescriber will conduct a thorough assessment to ensure safe, appropriate treatment selection.

Practical Considerations: Orlistat vs Wegovy Lifestyle Fit

Daily routine and lifestyle factors significantly influence the orlistat vs wegovy decision in practical terms. Orlistat requires taking one 120mg capsule with each main meal containing fat (up to three times daily), meaning you must remember to take medication at breakfast, lunch, and dinner. If you skip a meal or eat a fat-free meal, you omit that dose. This dosing schedule integrates easily for patients with regular eating patterns but can be challenging for shift workers, frequent travellers, or those with irregular meal timing. The need to plan for potential gastrointestinal side effects also requires consideration—access to toilet facilities and the possibility of urgency may impact work or social situations.

Wegovy offers a once-weekly injection schedule that many patients find more convenient than daily oral medication. After initial training (available through our pharmacy team), most patients self-administer the pre-filled pen at home on the same day each week, regardless of meal timing. The injection can be given at any time of day, with or without food, into the abdomen, thigh, or upper arm [2]. However, the injection format itself represents a barrier for some patients—needle anxiety is common, and proper injection technique and pen storage (refrigeration required) add practical requirements not present with oral orlistat capsules.

From a dietary perspective, the orlistat vs wegovy comparison reveals different nutritional approaches. Orlistat works optimally with a reduced-calorie, lower-fat diet (approximately 30% calories from fat), actively discouraging high-fat meals through its side effect profile. This creates a built-in behavioural reinforcement for healthier fat choices. Wegovy reduces overall appetite and portion sizes through central mechanisms, often leading to spontaneous calorie reduction without requiring specific macronutrient targets [3]. Some patients prefer orlistat's clear dietary framework, while others appreciate Wegovy's flexibility. During your consultation at Cured Pharmacy, our clinical team will help you assess which approach aligns better with your eating habits, daily schedule, and personal preferences.

Treatment Duration and Long-Term Use

Long-term treatment considerations differ in the orlistat vs wegovy context. Orlistat has over 20 years of safety data supporting extended use, with some patients remaining on treatment for several years to maintain weight loss [1]. UK prescribing guidelines typically recommend reviewing treatment at 12 weeks—if you have not lost at least 5% of initial body weight, discontinuation is advised. Wegovy trials have demonstrated safety and efficacy for up to 2 years, with ongoing studies examining longer-term use [2]. Both treatments show weight regain upon discontinuation in most patients, highlighting that obesity is a chronic condition requiring sustained intervention. Your prescriber will discuss realistic treatment timelines and maintenance strategies based on your individual response and goals.

Scientific References

1. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155-161. [accessed 15 August 2026]
2. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
3. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & Wadden, T. A. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.